Prediction of HER2 gene status in Her2 2+ invasive breast cancer: A study of 108 cases comparing ASCO/CAP and FDA recommendations

Modern Pathology

Volumn 22, Issue 3, 2009, Pages 403-409

  Chibon, Frédéric ^a   De Mascarel, Isabelle ^a   Sierankowski, Ghislaine ^a   Brouste, Véronique ^a   Bonnefoi, Hervé ^a   Debled, Marc ^a   Mauriac, Louis ^a   MacGrogan, Gaëtan ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Amplification; FISH; HER2; Immunohistochemistry

Indexed keywords

POLYCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CHROMOSOME 17; CLINICAL FEATURE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS; ONCOGENE NEU; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 61349131323     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.195     Document Type: Article

References (24)

1. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123-138.
2. Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2008;61:89-94.
3. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
5. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 2003;42:337-347.
6. Brunelli M, Manfrin E, Martignoni G, et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol 2008;129:907-911.
7. Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 2006;42:1501-1506.
8. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-398.
9. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer are we there yet? Am J Clin Pathol 2004;121(Suppl):S33-S49.
10. Goldhirsch A, Gelber RD. Life with consequences of breast cancer: pregnancy during and after endocrine therapies. Breast 2004;13:443-445.
11. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005;6:240-246.
12. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-2721.
13. Arnould L, Arveux P, Couturier J, et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007;13:6404-6409.
14. Torrisi R, Rotmensz N, Bagnardi V, et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 2007;43:2339-2344.
15. Lal P, Salazar PA, Ladanyi M, et al. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 2003;5:155-159.
16. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004;121:631-636.
17. McClintock B. The stability of broken ends of chromosomes in Zea Mays. Genetics 1941;26:234-282.
18. Debatisse M, Coquelle A, Toledo F, et al. Gene amplification mechanisms: the role of fragile sites. Recent Results Cancer Res 1998;154:216-226.
19. Ma Y, Lespagnard L, Durbecq V, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 2005;11:4393-4399.
20. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001;195:422-428.
21. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 2005;29:1221-1227.
22. Dal LL, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006;5:2572-2579.
23. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005;7:R267-R273.
24. Carter SL, Eklund AC, Kohane IS, et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043-1048.